Peptide aggregation in neurodegenerative disease.

In the not-so-distant past, insoluble aggregated protein was considered as uninteresting and bothersome as yesterday's trash. More recently, protein aggregates have enjoyed considerable scientific interest, as it has become clear that these aggregates play key roles in many diseases. In this review, we focus attention on three polypeptides: beta-amyloid, prion, and huntingtin, which are linked to three feared neurodegenerative diseases: Alzheimer's, "mad cow," and Huntington's disease, respectively. These proteins lack any significant primary sequence homology, yet their aggregates possess very similar features, specifically, high beta-sheet content, fibrillar morphology, relative insolubility, and protease resistance. Because the aggregates are noncrystalline, secrets of their structure at nanometer resolution are only slowly yielding to X-ray diffraction, solid-state NMR, and other techniques. Besides structure, the aggregates may possess similar pathways of assembly. Two alternative assembly pathways have been proposed: the nucleation-elongation and the template-assisted mode. These two modes may be complementary, not mutually exclusive. Strategies for interfering with aggregation, which may provide novel therapeutic approaches, are under development. The structural similarities between protein aggregates of dissimilar origin suggest that therapeutic strategies successful against one disease may have broad utility in others.

[1]  R. Wetzel,et al.  Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Tjernberg,et al.  Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand (*) , 1996, The Journal of Biological Chemistry.

[3]  G. Forloni,et al.  Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. , 1994, The Journal of biological chemistry.

[4]  W. Surewicz,et al.  Solution Structure of the E200K Variant of Human Prion Protein , 2000, The Journal of Biological Chemistry.

[5]  H. Vinters,et al.  Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. , 1999, Biochemistry.

[6]  J Collinge,et al.  Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. , 1999, Science.

[7]  S. Prusiner,et al.  Rapid Acquisition of β-Sheet Structure in the Prion Protein Prior to Multimer Formation , 1998, Biological chemistry.

[8]  L. Iversen,et al.  Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Murphy,et al.  A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. , 2001, Biophysical journal.

[10]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[11]  B. Chesebro,et al.  Species-Independent Inhibition of Abnormal Prion Protein (PrP) Formation by a Peptide Containing a Conserved PrP Sequence , 1999, Journal of Virology.

[12]  P. Fraser,et al.  pH-dependent structural transitions of Alzheimer amyloid peptides. , 1991, Biophysical journal.

[13]  F. Cohen,et al.  Scrapie infectivity is independent of amyloid staining properties of the N-terminally truncated prion protein. , 2000, Journal of Structural Biology.

[14]  J R Ghilardi,et al.  Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid. , 2000, Journal of structural biology.

[15]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[16]  B. Caughey Transmissible spongiform encephalopathies, amyloidoses and yeast prions: Common threads? , 2000, Nature Medicine.

[17]  L. Kiessling,et al.  Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. , 2001, Biochemistry.

[18]  P. Fraser,et al.  Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease , 1995, Nature Medicine.

[19]  M. Hecht,et al.  De novo amyloid proteins from designed combinatorial libraries. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Holzman,et al.  Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. , 1994, Biophysical journal.

[21]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[22]  W. Surewicz,et al.  The Role of Disulfide Bridge in the Folding and Stability of the Recombinant Human Prion Protein* , 2001, The Journal of Biological Chemistry.

[23]  J. Vincent,et al.  In Vivo Cytotoxicity of the Prion Protein Fragment 106–126* , 2000, The Journal of Biological Chemistry.

[24]  B. Solomon,et al.  Disaggregation of Alzheimer beta-amyloid by site-directed mAb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Fraser,et al.  Morphology and antibody recognition of synthetic β‐amyloid peptides , 1991 .

[26]  H. Paulson,et al.  Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.

[27]  B. Caughey,et al.  Inhibition of Interactions and Interconversions of Prion Protein Isoforms by Peptide Fragments from the C-terminal Folded Domain* , 2001, The Journal of Biological Chemistry.

[28]  P. Lansbury,et al.  The C‐Terminus of the β Protein is Critical in Amyloidogenesis a , 1993 .

[29]  S. Asano,et al.  Inhibition of Amyloid Protein Aggregation and Neurotoxicity by Rifampicin , 1996, The Journal of Biological Chemistry.

[30]  Regina M. Murphy,et al.  Kinetics of aggregation of synthetic β-amyloid peptide , 1992 .

[31]  Claudio Soto,et al.  β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.

[32]  F E Cohen,et al.  Pathologic conformations of prion proteins. , 1998, Annual review of biochemistry.

[33]  G. Forloni,et al.  Determination of solution conformations of PrP106-126, a neurotoxic fragment of prion protein, by 1H NMR and restrained molecular dynamics. , 1999, European journal of biochemistry.

[34]  Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. , 1999 .

[35]  H. Lehrach,et al.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Caughey,et al.  Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Collinge,et al.  Structural mobility of the human prion protein probed by backbone hydrogen exchange , 1999, Nature Structural Biology.

[38]  S. Hersch,et al.  Huntington aggregates may not predict neuronal death in Huntington's disease. , 1999, Annals of neurology.

[39]  C. Barrow,et al.  Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. , 1992, Journal of molecular biology.

[40]  T. Benzinger,et al.  Two-Dimensional Structure of β-Amyloid(10−35) Fibrils† , 2000 .

[41]  R. Glockshuber,et al.  Extremely rapid folding of the C-terminal domain of the prion protein without kinetic intermediates , 1999, Nature Structural Biology.

[42]  J T Finch,et al.  Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Hersch,et al.  Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .

[44]  D. Housman,et al.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Emmerling,et al.  Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[46]  K Wüthrich,et al.  NMR solution structure of the human prion protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Owen,et al.  Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. , 2000, The Biochemical journal.

[48]  J. Pettegrew,et al.  Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. , 1998, Life sciences.

[49]  J. Swatton,et al.  Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. , 1999, The Biochemical journal.

[50]  M. Findeis,et al.  Modified-peptide inhibitors of amyloid beta-peptide polymerization. , 1999, Biochemistry.

[51]  C M Dobson,et al.  Mutational analysis of the propensity for amyloid formation by a globular protein , 2000, The EMBO journal.

[52]  Carl W. Cotman,et al.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  P. Lansbury,et al.  Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. , 1999, Biochemistry.

[54]  L. Serpell,et al.  Molecular structure of a fibrillar Alzheimer's A beta fragment. , 2000, Biochemistry.

[55]  G P Bates,et al.  Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  A. Hackam,et al.  Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal Cells* , 2000, The Journal of Biological Chemistry.

[57]  J R Ghilardi,et al.  Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. , 2000, Biochemistry.

[58]  P. Lansbury,et al.  The C-terminus of the beta protein is critical in amyloidogenesis. , 1993, Annals of the New York Academy of Sciences.

[59]  He Li,et al.  Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity , 2000, Nature Genetics.

[60]  J. Straub,et al.  Simulation study of the structure and dynamics of the Alzheimer's amyloid peptide congener in solution. , 2001, Biophysical journal.

[61]  J. Kemp,et al.  Controlling Polymerization of β-Amyloid and Prion-derived Peptides with Synthetic Small Molecule Ligands* , 2000, The Journal of Biological Chemistry.

[62]  F E Cohen,et al.  Folding of prion protein to its native alpha-helical conformation is under kinetic control. , 2001, The Journal of biological chemistry.

[63]  P. Silver,et al.  Polyglutamine Expansions Proteolysis, Chaperones, and the Dangers of Promiscuity , 2000, Neuron.

[64]  W. Surewicz,et al.  Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. , 2000, Biochemistry.

[65]  T. Benzinger,et al.  Two-dimensional structure of beta-amyloid(10-35) fibrils. , 2000, Biochemistry.

[66]  M. Davies,et al.  In-situ atomic force microscopy study of beta-amyloid fibrillization. , 2000, Journal of molecular biology.

[67]  R. Cappai,et al.  Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrPC , 2000, Journal of neuroscience research.

[68]  Lars Terenius,et al.  A Molecular Model of Alzheimer Amyloid β-Peptide Fibril Formation* , 1999, The Journal of Biological Chemistry.

[69]  A. Fersht,et al.  Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[70]  R. Leapman,et al.  Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of β-sheets in Alzheimer's β-amyloid fibrils , 2000 .

[71]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[72]  R. Snell,et al.  Amyloid-like inclusions in Huntington’s disease , 2000, Neuroscience.

[73]  F. Cohen,et al.  Conformational propagation with prion‐like characteristics in a simple model of protein folding , 2001, Protein science : a publication of the Protein Society.

[74]  James R. Burke,et al.  Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening* , 2000, The Journal of Biological Chemistry.

[75]  Y. Kallberg,et al.  Prediction of Amyloid Fibril-forming Proteins* , 2001, The Journal of Biological Chemistry.

[76]  G. Forloni,et al.  Neurotoxicity of a prion protein fragment , 1993, Nature.

[77]  W. B. Stine,et al.  The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. , 1996, Journal of protein chemistry.

[78]  J. Smith,et al.  Dynamic simulation of the mouse prion protein. , 2000, Biopolymers.

[79]  R A Houghten,et al.  Inhibition of beta-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library. , 2000, Journal of structural biology.

[80]  Fran Maher,et al.  The Hydrophobic Core Sequence Modulates the Neurotoxic and Secondary Structure Properties of the Prion Peptide 106‐126 , 1999, Journal of neurochemistry.

[81]  D. Kirschner,et al.  Structural analysis of Alzheimer's beta(1-40) amyloid: protofilament assembly of tubular fibrils. , 1998, Biophysical journal.

[82]  T. Klockgether,et al.  Cell death in polyglutamine diseases , 2000, Cell and Tissue Research.

[83]  L. Serpell,et al.  Molecular Structure of a Fibrillar Alzheimer's Aβ Fragment† , 2000 .

[84]  Peter T. Lansbury,et al.  Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .

[85]  A. Doig,et al.  Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. , 2000, The Journal of biological chemistry.

[86]  A. Doig,et al.  Inhibition of Toxicity in the β-Amyloid Peptide Fragment β-(25–35) Using N-Methylated Derivatives , 2000, The Journal of Biological Chemistry.

[87]  R. Leapman,et al.  Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of beta-sheets in Alzheimer's beta-amyloid fibrils. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[88]  B. Seilheimer,et al.  The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. , 1997, Journal of structural biology.

[89]  P. Fraser,et al.  Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. , 1994, Journal of molecular biology.

[90]  M. Chesselet,et al.  Tissue-Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of Enhanced Levels of N- and C-Terminal htt Fragments in Huntington's Disease Striatum , 2001, The Journal of Neuroscience.

[91]  D. Owen,et al.  Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. , 2000, The Biochemical journal.

[92]  M. Citron,et al.  Aβ-Generating Enzymes Recent Advances in β- and γ-Secretase Research , 2000, Neuron.

[93]  W. B. Stine,et al.  The nanometer-scale structure of amyloid-Β visualized by atomic force microscopy , 1996 .

[94]  D. Kirschner,et al.  Kinetic theory of fibrillogenesis of amyloid beta-protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[95]  F E Cohen,et al.  Prion protein peptides induce alpha-helix to beta-sheet conformational transitions. , 1995, Biochemistry.

[96]  D. Housman,et al.  Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Fred E. Cohen,et al.  Folding of Prion Protein to Its Native α-Helical Conformation Is under Kinetic Control* , 2001, The Journal of Biological Chemistry.

[98]  L. Kiessling,et al.  A Strategy for Designing Inhibitors of β-Amyloid Toxicity* , 1996, The Journal of Biological Chemistry.

[99]  S. Prusiner,et al.  Structural changes in a hydrophobic domain of the prion protein induced by hydration and by ala-->Val and pro-->Leu substitutions. , 2000, Journal of molecular biology.

[100]  David R. Brown Prion Protein Peptides: Optimal Toxicity and Peptide Blockade of Toxicity , 2000, Molecular and Cellular Neuroscience.

[101]  L. Kiessling,et al.  Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. , 1999, Biochemistry.

[102]  D C Krakauer,et al.  Mapping the parameters of prion-induced neuropathology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[103]  H. Minakata,et al.  Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. , 2000, Biophysical journal.

[104]  G Klopman,et al.  Solution structure of residues 1-28 of the amyloid beta-peptide. , 1994, Biochemistry.

[105]  George B. Benedek,et al.  Kinetic theory of fibrillogenesis of amyloid β-protein , 1997 .

[106]  D. Kirschner,et al.  A beta fibrillogenesis: kinetic parameters for fibril formation from congo red binding. , 2000, Journal of structural biology.

[107]  A. Takashima,et al.  Three-dimensional structures of the amyloid beta peptide (25-35) in membrane-mimicking environment. , 1996, Biochemistry.